Skip to Content

Small Grants RFA


Funding Opportunity Description

WVCTSI is accepting Pilot Project Funding applications for clinical and translational research focusing on, but not limited to, specific health areas of importance to West Virginia and Appalachia at large. Of note, projects with significant laboratory based components must have very clear delineation of the plan for translation of the research with impact on human health.

The National Institutes of Health (NIH) defines clinical research as: (1) patient-oriented research; (2) epidemiologic and behavioral studies; and/or (3) outcomes research and health services research.  

Per the NIH, translational research includes:

  • The process of making discoveries in the research laboratory or in preclinical studies that will have an impact on human health and may lead to the development of studies in humans
  • The process of applying discoveries generated during research in the laboratory, and in preclinical studies, to the development of trials and studies in humans;
  • Research aimed at enhancing the adoption of best practices in the community.
  • Cost-effectiveness of prevention and treatment strategies are also important aspects of translational science.

Application Deadline: April 19, 2021 by 5 p.m. EST



For this funding cycle, the budget is limited to a maximum of $5,000 in total direct costs for a six (6) months.


Eligibility Information

  • Principal Investigator (PI) must hold a faculty appointment or equivalent at the time the award is
    announced. Appointments can be held at CAMC Institute/WVU Charleston, Marshall University,
    West Virginia School of Osteopathic Medicine, and West Virginia University.
  • For the purposes of this RFA, these are individuals who can independently apply for federal or nonfederal investigator-initiated, peer-reviewed Research Project Grants (RPG). Individuals holding
    postdoctoral fellowships or other positions that lack independent status are not eligible to lead pilot
  • Note that Marshall University faculty members must hold an appointment in either the School of
    Medicine or the School of Pharmacy. Other Schools and Colleges at Marshall University are NOT
    currently eligible for WVCTSI Pilot grants.


  • The Project lead for Pilot projects may not concurrently have funding from other IDeA Program award mechanisms (e.g. INBRE, COBRE).
  • Pilot projects may not overlap with other ongoing WVCTSI-funded projects.
  • Faculty named in the WVCTSI organization (i.e. program chairs and key personnel) are restricted from serving as PI on WVCTSI pilot grants, as well as prohibited from having funds directed to their labs or programs. However, such individuals may be included on pilot grants in supportive roles such as Co-Investigators, mentors, and consultants.
  • **No clinical trials allowed for this funding mechanism.


Any application previously been submitted to WVCTSI Pilot Grants Program, but not funded is eligible for resubmission once. PIs submitting a revised proposal must respond to the previous panel review summary and will have one additional page within their application to do so.

Resubmitted applications must be received by the relevant due dates, will be evaluated in competition with other pending applications in the appropriate area to which they are assigned, and will be reviewed according to the same evaluation criteria as new applications.

Regardless of designation, applications appearing to be resubmissions are regarded as such by the program and the panel, and compete on the same basis with all other applications submitted to the WVCTSI Pilot Grants Program during that funding cycle.

If you are planning on completing a resubmission, please contact the WVCTSI team prior to resubmitting your application.



Meg Haller, MPA, MSW - Pilot Grant Coordinator